The systemic lupus erythematosus (SLE) treatment pipeline is experiencing unprecedented expansion, driven by increasing disease awareness, rising pre ...

On May 7, 2025, the American College of Rheumatology (ACR) released the full guideline for diagnosing, monitoring, and treating lupus nephritis (LN), which appeared in Arthritis & Rheumatology.

Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 124,000 shares ...

Detailed price information for Vera Therapeutics Inc Cl A (VERA-Q) from The Globe and Mail including charting and trades.

Figure 1A (left): Kidney biopsy showing a normal glomerulus. Figure 1B (right): Kidney biopsy from a patient with class IV lupus nephritis showing a glomerulus with narrowing/closing of the ...

Detailed price information for Aurinia Pharm Ord (AUPH-Q) from The Globe and Mail including charting and trades.

Adult patients who met criteria for systemic lupus erythematosus and had active class III or IV lupus nephritis were eligible for this study. Exclusion criteria included eGFR lower <30 ml/min/1.73m 2 ...

The inclusion criteria encompassed the following: (1) age 18 years or older; (2) a diagnosis of class IV ± V LN confirmed by renal biopsy with complete ... Figure 1. Study flowchart. LN, lupus ...

lupus nephritis and 14 had non-proliferative disease (class 2 or pure class 5). Immunological testing was performed for C3 and C4 complement fractions, anti-double-stranded DNA, and anti-C1q ...

Objectives Primary: To validate a previously developed lupus nephritis (LN) histologic class predictor tool (III or IV±(V ... Student’s t-test or Mann-Whitney U test was used to compare means between ...

An estimated 30% to 50% of patients with SLE will later develop lupus nephritis. 2 The primary goal of lupus nephritis treatment is to avoid chronic kidney disease. The treatment regimen selected ...